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Abstract 
Background: The administration of endovenous immunoglobulins in patients with septic shock could be beneficial 
and preparations enriched with IgA and IgM (ivIgGAM) seem to be more effective than those containing only IgG. In 
a previous study Berlot et al. demonstrated that early administration of ivIgGAM was associated with lower mortality 
rate. We studied a larger population of similar patients aiming either to confirm or not this finding considering also 
the subgroup of patients with septic shock by multidrug-resistant (MDR) pathogens.
Methods: Adult patients with septic shock in intensive care unit (ICU) treated with ivIgGAM from August 1999 to 
December 2016 were retrospectively examined. Collected data included the demographic characteristics of the 
patients, the diagnosis at admission, SOFA, SAPS II and Murray Lung Injury Score (LIS), characteristics of the primary 
infection, the adequacy of antimicrobial therapy, the delay of administration of ivIgGAM from the ICU admission and 
the outcome at the ICU discharge. Parametric and nonparametric tests and logistic regression were used for statistic 
analysis.
Results: During the study period 107 (30%) of the 355 patients died in ICU. Survivors received the ivIgGAM earlier 
than nonsurvivors (median delay 12 vs 14 h), had significantly lower SAPS II, SOFA and LIS at admission and a lower 
rate of MDR- and fungal-related septic shock. The appropriateness of the administration of antibiotics was similar 
in survivors and nonsurvivors (84 vs 79%, respectively, p: n.s). The delay in the administration of ivIgGAM from the 
admission was associated with in-ICU mortality (odds ratio per 1-h increase = 1.0055, 95% CI 1.003–1.009, p < 0.001), 
independently of SAPS II, LIS, cultures positive for MDR pathogens or fungi and onset of septic shock. Only 46 patients 
(14%) had septic shock due to MDR pathogens; 21 of them (46%) died in ICU. Survivors had significantly lower SAPS 
II, SOFA at admission and delay in administration of ivIgGAM than nonsurvivors (median delay 18 vs 66 h). Even in this 
subgroup the delay in the administration of ivIgGAM from the admission was associated with an increased risk of in-
ICU mortality (odds ratio 1.007, 95% CI 1.0006–1.014, p = 0.048), independently of SAPS II.
Conclusions: Earlier administration of ivIgGAM was associated with decreased risk of in-ICU mortality both in 
patients with septic shock caused by any pathogens and in patients with MDR-related septic shock.
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Background
In the last few years it became clear that septic shock 
can occur in two different forms: the first is character-
ized by an excessive pro-inflammatory response due to 
the interaction between the host and the infecting germ 
whereas the other is associated with the progressive 
exhaustion of both the innate and adaptive immune sys-
tem; the consequent decrease in the number of B-cells 
and of the production of immunoglobulins (Ig) often 
leads to secondary infections which can negatively 
affect the clinical outcome [1, 2]. The role of endoge-
nous Ig has been enlightened by a number of investiga-
tions which demonstrated that (a) the concentrations of 
different classes of Ig were decreased both in commu-
nity- and ICU-acquired septic shock; and that (b) these 
findings were associated with a greater vasopressor 
requirement, higher incidence of ARDS and increased 
mortality [3–5]. The protective effects of Ig are ascribed 
to their pleiotropic actions, including the enhancement 
of bacterial and viral clearance, the decreased synthesis 
of several pro-inflammatory cytokines and the scaveng-
ing of apoptotic cells [6].
Despite a better knowledge of their mechanisms of 
action and some meta-analyses demonstrating that (a) 
the administration of polyclonal intravenous Ig (ivIg) was 
associated with an improved outcome in septic patients; 
and (b) this effect was more marked when the prepara-
tion used in the trial contained increased amount of IgA 
and IgM (12% each one) (ivIgGAM) [7–10], the previous 
as well as the current guidelines of the Surviving Sepsis 
Campaign (SSC) recommend against their use; this state-
ment is based on either the lack of randomized clini-
cal trials (RCT) satisfying the evidence-based medicine 
(EBM) standards and to the different composition of the 
ivIg used [11]. Independently by the SSC, not only the 
ivIgGAM are widely used but a new preparation contain-
ing almost double concentrations of IgM (⁓23%) and IgA 
(⁓21%) has been developed whose use has been associ-
ated with an improved survival in patients with com-
munity-acquired pneumonia enrolled in a recent RCT 
(CIGMA) [12]; noteworthy, this effect was more marked 
in patients with baseline elevated levels of C-reactive pro-
tein, low levels of IgM or a combination of these abnor-
malities, possibly indicating a subset of patients who 
could take the maximal advantage from this approach.
The beneficial effect of IgM could be ascribed to its 
pentameric structure, including the neutralization of 
exo- and endotoxins, the enhancement of opsoniza-
tion and phagocytosis and the increased bacterial lysis 
obtained via the activation of the alternative pathway 
of the complement system [12–21]; moreover, besides 
these anti-infective actions, IgM molecules have also 
some immunomodulatory effects such as the scavenging 
of excessive complement factors and the blunting of the 
production of some sepsis mediators [22].
As in a previous study Berlot et al. [23] demonstrated 
that in a group of severe sepsis and septic shock patients 
survivors were given ivIgGAM earlier than nonsurvi-
vors and that each 24-h delay was associated with > 2% 
increase in the mortality rate, we studied a much larger 
population of similar patients aiming either to confirm or 
not this finding considering also the site of infection and 
the responsible germs.
Patients and methods
The hospital pharmacy provided names of all patients 
with septic shock admitted in the intensive care 
unit (ICU) of the University of Trieste since August 
1999 to December 2016 and treated with ivIgGAM 
 (Pentaglobin®; Biotest, Dreieich, Germany). The medical 
records of these patients were retrospectively examined 
except for patients who died within 24 h from admission 
in ICU and patients who did not meet SEPSIS 3 criteria 
for septic shock [24] (see flowchart Fig. 1). As ivIgGAM 
are routinely used in our ICU, the study did not imply 
any active intervention other than the standard medi-
cal care, so that the local Ethical committee deemed the 
patients’ informed consent unnecessary. Critically ill 
adult patients with trauma, medical and surgical critical 
illnesses are admitted in this ICU, whereas patients with 
noncomplicated acute cardiac diseases and following car-
diac surgery are treated in another department; pediatric 
and obstetric patients are admitted to another hospital.
The overall treatment was based on the SSC guidelines 
[11]. In particular in our ICU, the antimicrobial therapy 
was and is currently based on local guidelines which 
are periodically updated according to the microbiologi-
cal reports; low-dose steroids at a dose not exceeding 
200 mg/day were administered in patients not responding 
Fig. 1 Flowchart with inclusion and exclusion criteria. ivIgGAM, 
intravenous IgM- and IgA-enriched immunoglobulins; ICU intensive 
care unit; LOS length of stay
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to fluids and vasoactive drugs. According to the interna-
tional guidelines, fluids were administered respecting 
3-h bundles. As an adjunctive treatment, every patient 
received the selective digestive tract decontamination 
(SDD) for the whole length of stay in ICU associated with 
iv cefotaxime for the initial 3 days. Oral and rectal swabs 
were obtained at admission and twice a week subse-
quently. Patients with a life expectancy < 3 months, with 
known immune depression (i.e., AIDS, acute leukemia.) 
and/or treated with immunosuppressant agents were not 
included in the study.
Septic shock was considered to be caused by MDR 
bacteria when cultures obtained within 12  h from the 
diagnosis were positive for at least one of the following: 
methicillin-resistant Staphylococcus aureus (MRSA), 
methicillin-resistant Staphylococcus epidermidis (MRSE), 
extended-spectrum beta-lactamase (ESBL)-producing 
Enterococcus faecium, vancomycin-resistant Enterococci 
(VRE), multidrug-resistant Acinetobacter, ESBL-produc-
ing Enterobacteriaceae, carbapenem-resistant Enterobac-
teriaceae and multidrug-resistant Pseudomonas.
The ivIgGAM were administered as adjunctive therapy 
at the dose of 250 mg/kg/day; the infusion lasted 10 h and 
was repeated for 3 days (total dose 750 mg/kg), according 
to the manufacturer’s indications.
Collected data included the demographic characteris-
tics of the patients (age and sex), the type of admission 
(surgical or medical admission), the diagnosis at admis-
sion, the SOFA score calculated the first day of admin-
istration of ivIgGAM (SOFA D1), the SAPS II score, the 
Murray Lung Injury Score (LIS), the site of occurrence of 
septic shock, which was considered ICU-acquired when 
it occurred ≥ 48  h after the admission, the primary site 
of infection, the antibiotics administered and their ade-
quacy, the microorganisms isolated within 12 h from the 
diagnosis, the interval elapsing from the ICU admission 
and the first administration of ivIgGAM, the  LOSICU and 
the outcome at the ICU discharge. The goal of the study 
was to estimate the effect of the timing of administration 
of ivIgGAM on in-ICU mortality in patients with septic 
shock caused either by antibiotic-sensible or MDR patho-
gens. Since it was not aimed to compare the effectiveness 
of different treatments, it was not necessary to identify a 
control group.
To assess these relationships, initial descriptive com-
parisons between survivors and nonsurvivors at dis-
charge from ICU were carried out. Continuous variables 
were described by median and interquartile range and 
compared with the Wilcoxon–Mann–Whitney test (and 
the ANOVA test in case of ivIgGAM delay, in order to 
compare also the means), whereas categorical vari-
ables were described by absolute and relative frequen-
cies and compared with the χ2 test and the z score for 
proportions. Then, univariable logistic regression mod-
els were estimated for each parameter and subsequently 
a multivariable logistic regression model was build; we 
selected the final subset of predictors by means of a back-
ward conditional step-wise procedure starting from the 
list of variables that resulted to be significantly associ-
ated with the outcome at univariable analyses. The Hos-
mer–Lemeshow test was used to assess the goodness of 
fit of estimated models. A p value < 0.05 was considered 
significant. Finally, the prediction accuracy of the mul-
tivariable regression model was evaluated by means of a 
Receiver Operating Characteristic (ROC) curve and the 
Area Under the Curve (AUC) was compared with that 
of the ROC curves of any of the parameters used in the 
model using the De Long test. The same analyses were 
applied to the subset of patients with septic shock caused 
by MDR bacteria, considering at univariable analysis 
a significant p value < 0.10 due to the small sample size, 
but maintaining at multivariable analysis a cutoff of p 
value < 0.05. To evaluate whether the effect of the early 
administration of ivIgGAM on the outcome had signifi-
cant interactions with some of the most relevant patient’s 
characteristics, we performed further subgroup analyses. 
Variables considered were: the primary site of infection, 
the result of the cultures and the SOFA score, as a patient 
severity index.
All statistical computations were calculated using the R 
statistical package, software version 3.3.3.
Results
During the considered period 355 patients met the inclu-
sion criteria: 107 of them (30%) died in ICU. All patients 
received the first dose of empirical antimicrobial therapy 
within 2  h from septic shock diagnosis. Cultures were 
positive in 264 patients (74%) (in particular 201 cases 
reported positive blood cultures) and negative in 58 
(17%). In 33 patients (9%) cultures within 12 h from the 
diagnosis were not obtained. The most frequently iso-
lated microorganisms were: Escherichia coli (91 cases), 
Enterococcus faecium (36), Klebsiella pneumoniae (27), 
methicillin-sensitive Staphylococcus aureus (26), Ente-
rococcus faecalis (25), MRSA (22), Pseudomonas aerugi-
nosa (18). The median of the delay in the administration 
of ivIgGAM from the admission in ICU was 12 h (inter-
quartile range 3-39). Even if the median value of delay 
was not significantly different between survivors and 
nonsurvivors at the Wilcoxon–Mann–Whitney test, 
the mean value was different (respectively, 36 vs 66  h, 
p = 0.002, ANOVA test) indicating a higher mean delay 
in the nonsurvivor group. The survivors had significantly 
lower SAPS II, SOFA and LIS score at admission and a 
lower rate of MDR-related septic shock. The distribu-
tion per year of enrollment was similar in the two groups 
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(Table  1). The univariable logistic regression showed 
a statistically significant association between the tim-
ing in the administration of ivIgGAM and the outcome 
(Table  2). The other variables significantly related to a 
higher risk of dying in ICU were higher SAPS II, SOFA 
D1 and LIS and cultures positive for MDR bacteria or 
fungi. We verified that the year of enrollment was not a 
confounding factor because this variable did not influ-
ence the mortality (Table 2). 
The multivariable analysis showed that the association 
between the delay in the administration of ivIgGAM and 
the outcome was independent from the other variables 
taken into account (for each 24-hour increase adjusted 
OR 1.15, CI 95% 1.05-1.27, p = 0.0005) (Table  3), Hos-
mer and Lemeshow test p value = 0.20. Put differently, 
in a patient with median SAPS II and median SOFA D1, 
without fungal infections, a 24-hour delay in ivIgGAM 
administration from the admission resulted in roughly 
a 2% increase in the probability of dying during his ICU 
stay. The estimated effect of delay in administration of 
ivIgGAM on the probability of in-ICU death is repre-
sented in Fig.  2 using the corresponding logit function 
Table 1 Characteristics of the studied patients subdivided into Survivors and Nonsurvivors at discharge from ICU
Variables are medians (interquartile range) or absolute frequencies (relative frequencies)
ivIgGAM Intravenous IgM- and IgA-enriched immunoglobulins; ICU intensive care unit; MDR multidrug resistant; SAPS II Simplified Acute Physiology Score; SOFA D1, 
sequential organ failure assessment calculated the first day of administration of ivIgGAM
All patients (355) Survivors (248) Nonsurvivors (107) p Value
Age (years) 68 (57-74) 68 (57–74) 70 (58–76) 0.27
Sex 0.197
 Female 151 (42.54%) 111 (44.8%) 40 (37.4%)
 Male 204 (57.46%) 137 (55.2%) 67 (62.6%)
SAPS II 53 (45–62) 51 (43–58) 57 (49–69) < 0.001
SOFA D1 11 (9–13) 10 (8–12) 12 (11–14) < 0.001
Murray Lung Injury Score 3 (1–5) 3 (1–5) 4 (3–6) < 0.001
Type of admission 0.052
 Surgical 264 (74.8%) 192 (77.7%) 77 (67.9%)
 Medical 89 (25.2%) 55 (22.3%) 34 (32.1%)
Onset of septic shock 0.08
 Extra ICU 265 (75.07%) 179 (72.5%) 86 (81.1%)
 Intra-ICU 88 (24.93%) 68 (27.5%) 20 (18.9%)
Primary site of infection < 0.001
 Abdomen 198 (55.77%) 150 (60.5%) 48 (44.9%) p = 0.006
 Skin 27 (7.61%) 15 (6.0%) 12 (11.2%)
 Bloodstream 11 (3.1%) 6 (2.4%) 5 (4.7%)
 Not identified 19 (5.35%) 11 (4.4%) 8 (7.5%)
 Lungs 64 (18.03%) 33 (13.3%) 31 (29.0%) p < 0.001
 Urinary tract 31 (8.73%) 28 (11.3%) 3 (2.8%) p = 0.018
 Central nervous system 5 (1.41%) 5 (2.0%) 0 (0.0%)
Adequacy of antimicrobial therapy 0.26
 No 45 (17%) 28 (15%) 17 (21%)
 Yes 219 (83%) 155 (84%) 64 (79%)
MDR bacteria 0.01
 Absent 277 (85.76%) 202 (89%) 75 (78.1%)
 Present 46 (14.24%) 25 (11%) 21 (21.9%)
Fungi 0.014
 Absent 262 (81.11%) 192 (84.6%) 70 (72.9%)
 Present 61 (18.89%) 35 (15.4%) 26 (27.1%)
Length of stay (days) 10 (6–17) 11 (6–17) 9 (3–17) 0.019
Year of enrollment 2011 (2008–2013) 2011 (2008–2013) 2011 (2008–2013) 0.57
Delay in ivIgGAM administration from admis-
sion in ICU (hours)
12 (3–39) 12 (3–33) 14 (3–66) 0.22
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estimated from the multivariable logistic regression 
model, adjusted to median value of SAPS II, SOFA D1 
and without fungal infection (these values were chosen 
as the most representative values in this population). 
As shown in Fig.  2, since the relationship between the 
delay in drug administration and the risk of death in ICU 
appeared linear, it is not possible to identify an optimal 
cutoff, as survival progressively increases with the preco-
ciousness of drug administration.
The ROC curve obtained from the model showed an 
AUC of 0.75 with 95% CI 0.69–0.81, significantly higher 
than the univariable logistic models considering SAPS II, 
SOFA D1 and fungal infection (p < 0.001) (Fig. 3).
During the study period only 46 patients (14%) met the 
diagnosis of septic shock due to MDR bacteria and 21 
of them (46%) died in ICU (Additional file 1). The most 
frequently isolated MDR microorganisms were: MRSA 
(45.6%) and Escherichia coli ESBL (21.7%). In this group 
of patients also an earlier administration of ivIgGAM was 
associated with a better outcome (see Additional file 1).
Finally, we evaluated the effect of the timing of admin-
istration of ivIgGAM on death in ICU in different sub-
groups. In the subgroup with pulmonary infection (64 
patients), univariable analysis did not show a statistically 
significant association between delay in ivIgGAM admin-
istration and mortality (p = 0.557). In the remaining cases 
the correlation was significant (p = 0.001). We also ana-
lyzed the subgroup of patients with abdominal infection 
(198 patients): in this group the relationship between the 
delay of ivIgGAM administration and the risk of death in 
ICU was statistically significant (p = 0.008).
Considering the results of the cultures, the sample was 
divided into two subgroups: patients with positive cul-
tures within 12 h from the diagnosis of septic shock (264) 
and patients with negative cultures (58). In this analy-
sis, patients in whom the cultures were not performed 
within 12  h (33) were not taken into consideration. In 
the subgroup of patients with positive cultures, the delay 
in administration of ivIgGAM from admission in ICU 
remained significantly correlated with the risk of death 
at both univariable (p = 0.001) and multivariable analysis 
(p < 0.001). In the subgroup of patients with negative cul-
tures, this correlation was not confirmed (p = 0.994), but 
the small size of the sample should be taken into account.
To assess if the relationship between the timing of 
ivIgGAM administration and death in ICU depended 
on severity, the sample was divided into two subgroups 
according to the median value of the SOFA score of the 
first day of administration of ivIgGAM (SOFA score 
median value = 11, see Table 1).
At univariable analyses, the relationship was less sta-
tistically significant in the subgroup with SOFA score 
greater than the median (OR 1.004, p = 0.05), while it was 
highly significant in the subgroup with SOFA score lower 
than the median (OR 1.005, p = 0.01). At multivariable 
analyses the significance of the effect of early ivIgGAM 
administration was similar in the two subgroups (in both 
cases, p <= 0.02), even if the estimated effect was stronger 
in the less severe patients (see Additional file 1).
No adverse effects attributable to the ivIgGAM were 
observed.
Discussion
In septic shock the dysregulation of both arms of the 
immune system accounts for both the initial hyperin-
flammatory phase and for the subsequent shift toward a 
more advanced stage in which an immunoparalysis can 
dominate the clinical course, leading to secondary infec-
tions by MDR germs and to the reactivation of latent 
viruses [1, 25]. This cycle can recur several times during 
the ICU stay, thus leading to a chronic critical illness, 
Table 2 Univariable logistic regression analyses of  risk 
factors for in-ICU mortality
ivIgGAM Intravenous IgM- and IgA-enriched immunoglobulins; ICU intensive 
care unit; MDR multidrug resistant; SAPS II Simplified Acute Physiology Score; 
SOFA D1 sequential organ failure assessment calculated the first day of 
administration of ivIgGAM
OR 95% CI p Value
Age 1.004 0.98–1.02 0.62
Sex (male) 1.36 0.86–2.17 0.198
SAPS II 1.046 1.028–1.065 < 0.001
SOFA D1 1.24 1.15–1.35 < 0.001
Murray Lung Injury Score 1.14 1.04–1.24 0.003
Onset of septic shock (Intra-ICU) 0.61 0.34–1.06 0.08
Type of admission (Surgical) 0.607 0.37–1.006 0.053
MDR bacteria 2.26 1.18–4.28 0.01
Fungi 2.037 1.14–3.62 0.01
Year of enrollment 0.97 0.91–1.023 0.253
Adequacy of antimicrobial therapy 0.68 0.348–1.328 0.259
Delay in ivIgGAM administration 
from admission in ICU
1.0039 1.0013–1.0066 0.0035
Table 3 Multivariable logistic regression analysis of  risk 
factors for in-ICU mortality
ivIgGAM Intravenous IgM- and IgA-enriched immunoglobulins; ICU intensive 
care unit; SAPS II Simplified Acute Physiology Score; SOFA D1 sequential organ 
failure assessment calculated the first day of administration of ivIgGAM
OR 95% CI p Value
SAPS II 1.04 1.018–1.06 < 0.001
SOFA D1 1.15 1.052–1.27 0.003
Fungi 2.21 1.17–4.18 0.015
Delay in ivIgGAM administra-
tion from admission in ICU
1.006 1.003–1.009 < 0.001
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which is rather common among elderly patients affected 
by preexistent co-morbidities as well as in debilitated 
subjects of all ages [26, 27].
Currently, steroids and ivIg are the only immunomod-
ulatory agents available, pending the results of several 
clinical trials with more innovative agents [28, 29]. How-
ever, it appears that what can be relatively beneficial in 
the initial stage of sepsis and septic shock, such as ster-
oids, could be harmful in the following one [1, 29]; con-
versely, the ivIgGAM are suitable both in its early and in 
the advanced phase, due to their combined antibacterial 
and immunomodulatory properties [14–21]. The biologi-
cal rationale for their administration can be found in the 
results of some studies demonstrating that not only low 
levels of IgG, IgM and IgA measured at the admission but 
also their failed increase during the ICU stay were associ-
ated with both the transition from severe sepsis to septic 
shock and with a reduced survival [30–32]; yet, despite 
these evidences, the role of ivIgGAM in the treatment of 
septic shock remains controversial notwithstanding their 
use began several decades ago.
Basically, supporters of ivIgGAM claim that (a) their 
dual action on the immune response make them valuable 
throughout the whole clinical course of sepsis and sep-
tic shock and that (b) their positive effect on the outcome 
has been confirmed by a number of meta-analyses [7–
10]. On the other front, opponents reply that the clinical 
studies published so far suffer from such an elevated het-
erogeneity of patients and of preparations used, so that 
it is impossible to draw definite conclusion from their 
results [13]. Despite these biases, the ivIgGAM are widely 
used and the German guidelines for the treatment of sep-
sis [33] suggest considering their administration in sep-
tic shock patients while they discourage the use of ivIg. 
Therefore, it appears that more data about the clinical use 
of ivIgGAM are keenly needed. The results of this study 
not only confirm some investigations but also add further 
information.
First, although there was a small difference in the tim-
ing of administration of ivIgGAM between S and NS, 
their early administration influenced the outcome; actu-
ally, a time effect has been demonstrated previously by 
Berlot et al. [23] who reported a 3% increase in mortal-
ity for every 24  h of delay and by Cavazzuti et  al. [34] 
who demonstrated a reduced mortality rate in septic 
shock patients treated with ivIgGAM within 24  h after 
shock onset. This finding recalls what has been reported 
in other investigations, which demonstrated an increase 
in mortality for each hour of delay in the administration 
of antibiotic [35–37]. The positive effect of ivIgGAM on 
the outcome persisted across the whole period of the 
study and was independent of other variations of the 
overall treatment. As shown by subgroup analyses, the 
benefit of early ivIgGAM administration appears to be 
more intense in clinically less severe patients, as already 
reported in the literature [38] and greater for abdominal 
primary site of infection. This time effect appears to be 
independent from the adequacy of the antibiotic therapy 
Fig. 2 Logit function from the multivariable logistic regression model in the group of all patients (right) showing the effect of delay in 
administration of IgM-enriched immunoglobulins on the probability of in-ICU death (solid line) with 95% confidence interval (gray area) adjusted to 
median value of SAPS II, SOFA D1 and without fungal infection. Comparison with logit functions from the multivariable logistic regression model for 
MDR-positive patients adjusted for median value of SAPS II (left). ivIgGAM, intravenous IgM- and IgA-enriched immunoglobulins; ICU, intensive care 
unit; MDR, multidrug resistant; SAPS II, Simplified Acute Physiology Score; SOFA D1, sequential organ failure assessment calculated the first day of 
administration of ivIgGAM
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since this latter variable did not differ among the two 
groups.
Second, this “time window effect” was present also in 
the group of patients whose infections were caused by a 
wide array of MDR pathogens. Although the timing of 
ivIgGAM administration was not specifically addressed 
in their studies, also Busani [39] and Giamarellos [40] 
demonstrated an increased survival in MDR germs-
related septic shock treated with ivIgGAM as compared 
with the control group. However, it is worthwhile to 
remark that (a) the rate of MDR infections in our popu-
lation was considerably lower than the one reported in 
these studies and that (b) since only 1 out of 3 cases of 
MDR-related septic shock was ICU-acquired, it is pos-
sible that the administration of ivIgGAM in patients 
already admitted to the ICU prevented their coloniza-
tion and subsequent infection with these germs. Then, 
it is hypothesizable that in the acute phase the ivIgGAM 
could act by increasing the bacterial clearance and reduc-
ing the hyperinflammatory reaction while in the later 
one they could contribute to restore the compromised 
immune capabilities by replenishing the IgM and IgA 
stores.
Our study has some limitations, including (a) the 
absence of the EBM criteria such as the randomization 
of the patients and their prolonged time of enrollment 
and lack of validation of the results in an independent 
cohort; however, as stated by some authors [29, 41] the 
past issues of the SSC guidelines contained several rec-
ommendations derived from the results of EBM- based 
Fig. 3 ROC curves comparing the predictive accuracy of the multivariable regression model (red curve) for all patients with each parameter used in 
the model: SAPS II (gray curve), SOFA D1 (green curve) and fungal infection (blue curve). SAPS II, Simplified Acute Physiology Score; SOFA, sequential 
organ failure assessment calculated the first day of administration of ivIgGAM
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RCTs that were not confirmed by subsequent studies 
and were removed later on; (b) the lack of a biological 
marker, such as the measurement of the blood levels of 
CRP and PCT and/or IgG, IgM and IgA suited to trigger 
the administration of ivIgGAM; actually, this reflects the 
real-world scenario because the results of these and other 
tests evaluating the immune capability are not univer-
sally available and, more important, what is a “safe” con-
centration of endogenous IgM and IgA in septic shock 
patients is not clear [13]; (c) due to the wide time span of 
the study, we could not establish precisely the rate of the 
appropriate antimicrobial treatment; however, as antibi-
otics were given according to the yearly updated hospital 
guidelines based on the local microbiological findings, we 
guess that it was evenly distributed among survivors and 
deceased patients.
Conclusions
In our experience, the administration of ivIgGAM was 
safe and well tolerated. Overall, survivors were treated 
earlier than nonsurvivors and this finding was present 
also in patients with MDR-associated septic shock, a spe-
cific sepsis population with high mortality risk.
In the perspective of personalized medicine, further 
studies and particularly RCTs are needed to identify 
the characteristics of the best septic shock candidate to 
receive ivIgGAM as adjunctive treatment. Our study 
contributes by showing the potential effect of the time 
factor on the effectiveness of ivIgGAM.
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